Istituto Tumori della Romagna (IRST)

Meldola 47014

0 studies enrolling now · 1 studies all time

What they study most

Myelofibrosis

Studies at this site

• An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib — Status unconfirmed